Dr. David Podwall Speaks with Newsday - “Mount Sinai and UnitedHealthcare reach deal”
3/20/2024 - Newsday interviews Dr. David Podwall, President of the Nassau County Medical Society regarding contract negotiations between Mt. Sinai and United Healthcare
Dr. David Podwall Speaks to CBS News about the Change Healthcare Cyberattack.
03/14/2024 - Change Healthcare Cyberattack impacts care to millions of Americans. A “nightmare” scenario as described by Dr. David Podwall in this interview
Dr. David Podwall speaks with News Channel 12 regarding the crisis created by the Change Healthcare cyberattack.
03/08/24 - Patients and health care providers have been struggling with various issues following a recent cyberattack on Change Healthcare, which is owned by UnitedHealth Group.
Dr. David Podwall is president of Nassau County Medical Society. He described the hack as “an absolute nightmare for most of the physicians around Long Island.”
The Killer Instinct: Using natural killer therapy to treat Alzheimer’s - An Interview with Dr. Vincent DeOrchis
02/21/24 - DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis, clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s.
In October 2023, pharmaceutical company NKGen Biotech released data from its Phase I clinical trial on the use of its investigational natural killer therapy, SNK01, to treat patients with Alzheimer’s disease. Though the study was small and designed to primarily assess SNK01’s safety, data indicate that the therapy may do more than slow the progression of Alzheimer’s disease. The FDA has also granted Compassionate Use to SNK01 and the therapy is currently being used to treat a patient with Alzheimer’s.
Dr. David Podwall, President of the Nassau County Medical Society, meets with Dr. Mandy Cohen, Director for the Centers of Disease Control (CDC)
11/20/23 - Dr. David Podwall meets with Director of the Center for Disease Control (CDC) Dr. Mandy Cohen
Congratulations to Dr. David Podwall, President of the Nassau County Medical Society and recipient of this year's Long Island Herald Excellence in Healthcare Award!
10/02/2023- The Excellence in Healthcare Awards were first presented in 2022. Dr. David Podwall, physical at Neurological Associates of Long Island and president of the Nassau County medical Society was a distinguished recipient of the 2023 Excellence in Healthcare Award for his dedicated service to his community.
Dr. Vincent DeOrchis interviewed by WPIX’s Marvin Scott regarding the first patient in the U.S. treated with an experimental therapy developed by NKGen Biotech for advanced Alzheimer’s type dementia
Dr. Vincent DeOrchis, interviewed by WPIX’s Marvin Scott regarding the treatment of the first patient in the United States with a experimental adoptive cellular immunotherapy developed by NKGen Biotech for the treatment of advanced Alzheimer’s type dementia
CGRP - A New Weapon in the Battle for Migraine Freedom
CGRP was first identified as a molecule of interest in the headache-pain pathway in 1986, but it wasn’t until 2000 when the first agents targeting the CGRP receptor (“gepants”) were developed. The first proof-of-concept study which took place in 2004 demonstrated a significant reduction in migraine symptoms when administered during the attack. Unfortunately future progress was stymied in 2009 when an early molecule, oral talcagepant, was associated with elevated liver enzymes and the trial was subsequently halted. The progress these agents made nevertheless supported further development and spurred the creation of second generation agents which showed far more promise without the risk of liver toxicity and better tolerability than was seen with the triptan agents.
Dr. DeOrchis and NKMAX partner to obtain FDA clearance for experimental Alzheimer‘s disease drug for compassionate use in U.S.
As reported in Pulse News, “NKMAX, a NK cell-based immunotherapy company in Korea, Wednesday said an investigational cell therapeutic SNK01 from its subsidiary NKGen Biotech (formerly NKMAX America) has received approval from the U.S. Food and Drug Administration (FDA) for patients with Alzheimer’s disease in compassionate use programs…Approval was given to Dr. Vincent Deorchis of St. Francis Hospital in New York, and he will use SNK01 for the treatment of eligible patients.”
St. Francis neuroscience team under leadership of Dr. DeOrchis introduce the Ceribell portable EEG system at St. Francis Hospital
Dr. DeOrchis, Director of Neurology at St. Francis Hospital, Introduces the Ceribell Portable EEG System for Rapid Critical Care Brain Monitoring
David Podwall, M.D., President-Elect of the Nassau County Medical Society named Top Business Leader in Nassau County
David Podwall, M.D., President-Elect of the Nassau Country Medical Society named Top Business Leader
Advancements in the Treatment of Multiple Sclerosis - 2022 Update
Over the past two decades, the field of multiple sclerosis (MS) has achieved significant milestones, particularly in advancing the understanding of disease pathogenesis and available treatments for patients living with MS. Refinements of diagnostic criteria and a revolutionary expansion of therapeutics, targeting both relapsing and progressive forms of MS, have made notable impacts on patient outcomes and quality of life. In contrast to the early 1990s, when only steroids could manage acute exacerbations, there are now over 20 FDA approved disease modifying therapies in this brimming armamentarium. Despite such advancements, there is still much work to be done to improve MS care.
FDA Approves First Treatment of Alzheimer’s Disease in Almost 20 Years
On June 7, 2021, the FDA made a controversial and unexpected decision to greenlight a novel therapy for Alzheimer’s disease, the first approved for this condition since 2003. ADUHELM (aducanumab), manufactured by Biogen, marks a new class of cognitive therapy – a monoclonal antibody directed at amyloid beta aggregates and soluble oligomers, the pathologic hallmark of Alzheimer’s disease.